RITTER PHARMACEUTICALS INC
Los Angeles, California, United States · Artificial Intelligence, Biotechnology, Blockchain
Ritter Pharmaceuticals discovers and commercializes treatments for gastrointestinal diseases.
Key facts
- Headquarters
- Los Angeles, California, United States
- Employees
- 11
- Industries
- Artificial Intelligence, Biotechnology, Blockchain
- Status
- Public (FFR)
- Website
- aixcrypto.com
- Company page
Recent activity at RITTER PHARMACEUTICALS INC
- : SEC 8-K (1.01): On October 12, 2026, FF EAI Robotics Ecosystem Inc. entered into a Transaction Agreement with Smart Technology Holdings Ltd. and Faraday Future Intelligent Electric Inc. to acquire FFAI's robotics business. This acquisition involves paying a Purchase Price of US$200 million adjusted for outstanding options. A special committee of independent directors determined that the transaction is fair and in the best interests of the Company. The deal will culminate in a merger with FFAI's subsidiary, RobotCo, which will become a wholly owned subsidiary of FF EAI Robotics Ecosystem Inc.
- : SEC 8-K (7.01): On September 29, 2026, AIxCrypto Holdings, Inc. filed a Certificate of Amendment to change its corporate name to 'FF EAI Robotics Ecosystem Inc.' The amendment will take effect at 12:01 a.m. Eastern Time on September 30, 2026. This change reflects a significant strategic rebranding, likely aimed at aligning the company’s identity with its operations in the robotics ecosystem sector. The registration was completed following a unanimous written consent of the board.
- : SEC 8-K (8.01): On September 25, 2026, AIxCrypto Holdings, Inc. entered into a non-binding term sheet with Faraday Future Intelligent Electric Inc. concerning the proposed acquisition of all outstanding equity interests of RobotCo, the parent company of Faraday Future's robotics business. This strategic move could significantly enhance AIxCrypto's portfolio by integrating advanced robotics technology. The transaction excludes outstanding options to purchase equity in RobotCo, indicating a focused approach on equity acquisition. The closing is contingent on various unnamed conditions, emphasizing the preliminary nature of the agreement.
- : SEC 8-K (5.02):
- : SEC 8-K (7.01): On August 18, 2026, AIxCrypto Holdings, Inc. announced a significant strategic shift towards robotics operations and commercialization. The company revealed its plan to exit from its Digital Asset Treasury strategy to prioritize its resources on robotics. This transition was highlighted by RoboShare completing its first paid commercial order on August 15, 2026, indicating the start of commercial operations and initial revenue generation. The company emphasized its near-term objectives of validating repeat demand and expanding its operations in Los Angeles and other cities, thereby marking a crucial pivot in its business focus.
- : SEC 8-K (7.01):
- : SEC 8-K (1.01): On July 29, 2026, AIxCrypto Holdings, Inc. entered into a Consulting Agreement with Aibot US Operation Inc, effective from July 16, 2026, and lasting until July 15, 2027, unless terminated earlier. Aibot will provide a consulting team of four personnel focused on finance, capital markets, and HR/legal coordination, with a monthly fee of $50,000 and reimbursement of expenses capped at $500 per month. The agreement is a related party transaction since Jerry Wang, CEO of AIxCrypto, is also on Aibot's board. The terms of the Agreement were reviewed and approved by the disinterested members of the Board and Audit Committee.
- : SEC 8-K (7.01): On June 22, 2026, AIxCrypto Holdings, Inc. announced its participation at Automate 2026, the largest automation and robotics exhibition in North America. The press release detailed the official launch of RoboShare, a platform for on-demand robot rentals, and introduced AIXC01, a new infrastructure network for autonomous assets. Additionally, the Company presented its comprehensive strategy integrating Embodied AI with Web3, which includes innovative concepts such as the 'Robot Second Life Cycle' and strategies for ground-air integration in the low-altitude economy. This event is significant as it showcases the Company's commitment to advancing automation and robotics technologies in a rapidly evolving market.
- : SEC 8-K (1.01): On June 16, 2026, AIxCrypto Holdings, Inc. entered into a Material Definitive Agreement with Gold King Arthur Holding Limited for a common shares purchase agreement. The Company agreed to sell up to $50,000,000 of its common shares in a private placement, representing up to 19.99% of the voting power of the shares prior to the agreement execution. The proceeds will be used in accordance with the Prospectus and will also involve an upfront fee of $100,000 paid to the Purchaser. This agreement allows for additional purchases under certain conditions, with a fee structure of 3% on the gross purchase amount going to the Purchaser.
- : SEC 8-K (5.02):
RITTER PHARMACEUTICALS INC funding history
| Date | Round | Amount |
|---|---|---|
| Nov 2018 | Venture | $6.0M |
Leadership
- William Merino, Director
- Michael Step, Director
- Matthew Foehr, Director
- Paul Maier, Director
- Noah Doyle, Director
- Ira Ritter, Executive Officer, Director
- Andrew Ritter, Executive Officer, Director
- John Beck, Executive Officer
Verified email and direct lines for RITTER PHARMACEUTICALS INC’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Employee benefit plans
RITTER PHARMACEUTICALS INC files 2 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Companies similar to RITTER PHARMACEUTICALS INC
- Reltime · Artificial Intelligence, Blockchain, Cryptocurrency, Finance, Financial Services, Fintech, Machine Learning
- PERPTools · Artificial Intelligence, Blockchain, Cryptocurrency, Financial Services, Fintech, Machine Learning
- Evernorth · Biotechnology, Blockchain, Cryptocurrency, Finance, Financial Services, Fintech
- AGRIFORCE GROWING SYSTEMS LTD · Artificial Intelligence, Blockchain, Cryptocurrency, Finance, Financial Services, Fintech
- Blum · Artificial Intelligence, Blockchain, Cryptocurrency, Finance, Financial Services, Fintech
About RITTER PHARMACEUTICALS INC: questions and answers
What does RITTER PHARMACEUTICALS INC do?
Ritter Pharmaceuticals discovers and commercializes treatments for gastrointestinal diseases.
Where is RITTER PHARMACEUTICALS INC headquartered?
RITTER PHARMACEUTICALS INC is headquartered in Los Angeles, California, United States.
How many employees does RITTER PHARMACEUTICALS INC have?
RITTER PHARMACEUTICALS INC has about 11 employees.
Has RITTER PHARMACEUTICALS INC raised funding?
Yes. Fundz has recorded 1 funding event for RITTER PHARMACEUTICALS INC. The most recent, $6.0M, was in Nov 2018.
What is the latest news on RITTER PHARMACEUTICALS INC?
On Oct 12, 2026, SEC 8-K (1.01): On October 12, 2026, FF EAI Robotics Ecosystem Inc. entered into a Transaction Agreement with Smart Technology Holdings Ltd. and Faraday Future Intelligent Electric Inc. to acquire FFAI's robotics business. This acquisition involves paying a Purchase Price of US$200 million adjusted
Is RITTER PHARMACEUTICALS INC a public company?
Yes. RITTER PHARMACEUTICALS INC is publicly traded under the ticker FFR.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy